Drug Profile
Research programme: enzyme inhibitors - Bristol-Myers Squibb
Alternative Names: IDO1-inhibitor - Bristol-Myers SquibbLatest Information Update: 28 Jan 2019
Price :
$50
*
At a glance
- Originator Flexus Biosciences
- Developer Bristol-Myers Squibb
- Class Antineoplastics; Small molecules
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Tryptophan oxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 08 Apr 2015 Flexus Biosciences has been acquired by Bristol-Myers Squibb
- 01 Dec 2014 Preclinical trials in Cancer in USA (Parenteral)